A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
Transplantation
; 106(2): e153-e157, 2022 02 01.
Article
in En
| MEDLINE
| ID: mdl-34519680
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
Antibodies, Monoclonal, Humanized
/
Transplant Recipients
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
/
Hospitalization
Type of study:
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Transplantation
Year:
2022
Document type:
Article
Affiliation country:
Canada
Country of publication:
United States